{
    "clinical_study": {
        "@rank": "40370", 
        "arm_group": {
            "arm_group_label": "allogeneic MMSCs infusion", 
            "arm_group_type": "Other", 
            "description": "Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy  subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion."
        }, 
        "brief_summary": {
            "textblock": "Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent\n      high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive\n      bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion\n      two hours prior to autologous peripheral blood cells infusion. This is a single arm study\n      with no control. All patients receive cell therapy."
        }, 
        "brief_title": "Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neutropenic Enterocolitis", 
            "Myeloablative Chemotherapy Induced Bone Marrow Aplasia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia, Aplastic", 
                "Pancytopenia", 
                "Enterocolitis", 
                "Enterocolitis, Neutropenic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with verified diagnosis Hodgkin's lymphoma or non-Hodgkin's lymphoma will undergo\n      peripheral blood stem cell mobilisation and collection (chemotherapy + G-CSF or\n      G-CSF+Plerixafor).\n\n      After that high-dose chemotherapy will be performed according to protocols ICE and BEAM\n      (standard scheme).\n\n      Patient will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells\n      infusion 48 hours after last administration of cytotoxic agent . Number of cells calculated\n      according to patient's body weight (1,5-2,0 mln of cells/kg), time of infusion - 30 minutes.\n      Two hours later patient will receive autologous peripheral blood cells infusion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient suffers from Hodgkin's lymphoma, non-Hodgkin's lymphoma with complete or\n             partial  remission.\n\n          -  Patient is candidate to high-dose chemotherapy with subsequent autologous\n             hematopoietic stem cell transplantation.\n\n          -  Absence of  infection, cardiovascular, respiratory, renal and hepatic dysfunctions,\n             focal neurological symptoms.\n\n          -  Karnofsky score at least 70.\n\n          -  Patient successfully undergone mobilization of peripheral  blood stem cells.\n\n          -  Patient is familiar with Participant information sheet.\n\n          -  Patient signed informed consent form.\n\n        Non-inclusion Criteria:\n\n          -  Severe chronic comorbidity with symptoms of organ or system failure.\n\n          -  Significant abnormalities in laboratory tests.\n\n          -  Participation in other clinical trials (or intake of study drugs) within prior 3\n             months.\n\n          -  Conditions restricting commitment to participating in the trial (dementia,\n             neuropsychiatric disorders, drug and alcohol abuse)\n\n          -  Patients with malignant solid tumors.\n\n          -  Patients with medical history of heterotopic ossification.\n\n        Exclusion Criteria:\n\n          -  Progression or relapse of lymphoma during therapy.\n\n          -  Confirmed syphilis, HIV,  hepatitis B or C infection\n\n          -  Absence of clinical and laboratory signs of hematopoietic recovery and persistent\n             enterocolitis at day 14  after the manipulation (Visit 15). While the patient remains\n             in the hospital and continues treatment according to requirements of standard therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145923", 
            "org_study_id": "RU-FMBC-05-01-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "allogeneic MMSCs infusion", 
                "intervention_name": "Peripheral blood stem cell mobilisation and collection", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "allogeneic MMSCs infusion", 
                "description": "High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)", 
                "intervention_name": "High-dose chemotherapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "allogeneic MMSCs infusion", 
                "intervention_name": "Bone marrow derived allogeneic MMSCs infusion", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "allogeneic MMSCs infusion", 
                "intervention_name": "Autologous peripheral blood stem cells infusion", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hodgkin Lymphoma", 
            "Non-Hodgkin's Lymphomas", 
            "Allogeneic Mesenchymal Stem Cell Transplantation", 
            "Autologous Peripheral Blood Stem Cell Transplantation", 
            "Neutropenic Enterocolitis", 
            "Myeloablative Chemotherapy", 
            "Bone Marrow Aplasia"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Moscow", 
                    "country": "Russian Federation", 
                    "zip": "123182"
                }, 
                "name": "State Research Center Burnasyan Federal Medical Biophysical Center FMBA of Russia"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effectiveness and Safety of Intravenous Infusion of Bone Marrow Derived Allogeneic Multipotent Mesenchymal Stromal Cells for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis in Hematological Patients With Aplasia After High-dose Chemotherapy.", 
        "overall_official": [
            {
                "affiliation": "Burnasyan Federal Medical Biophysical Center", 
                "last_name": "Zaryi Simavonyan, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Burnasyan Federal Medical Biophysical Center", 
                "last_name": "Ilya I Eremin, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of  serious adverse events (SAEs) and serious adverse reactions (SARs)", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145923"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Burnasyan Federal Medical Biophysical Center", 
            "investigator_full_name": "Zarui Simavonyan", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Monitoring of time of hematopoietic recovery assessed by complete blood count", 
                "measure": "Time of hematopoietic recovery", 
                "safety_issue": "No", 
                "time_frame": "Follow up to completion (up to 3 months after treatment)"
            }, 
            {
                "description": "Monitoring of frequency (number of participants) and severity of neutropenic enterocolitis during the study period", 
                "measure": "Neutropenic enterocolitis", 
                "safety_issue": "No", 
                "time_frame": "Follow up to completion (up to 3 months after treatment)"
            }, 
            {
                "description": "Monitoring of frequency and severity of infectious complications during the study period. Frequency of infectious complications will be represented in number of infections verified by clinical, instrumental examination and/or laboratory methods.", 
                "measure": "Infectious complications", 
                "safety_issue": "No", 
                "time_frame": "Follow up to completion (up to 3 months after treatment)"
            }, 
            {
                "description": "Monitoring of frequency (number of participants) of transfusion needs during neutropenic period", 
                "measure": "Transfusion needs", 
                "safety_issue": "No", 
                "time_frame": "Follow up to completion (up to 3 weeks after treatment)"
            }
        ], 
        "source": "Burnasyan Federal Medical Biophysical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Burnasyan Federal Medical Biophysical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}